Indication
Idiopathic Inflammatory Myopathy
2 clinical trials
2 products
Clinical trial
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory MyopathyStatus: Recruiting, Estimated PCD: 2027-09-01
Product
EFG PH20Product
EFG PH20 SCClinical trial
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory MyopathyStatus: Recruiting, Estimated PCD: 2026-12-01